CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...

Out of all of the special options we uncovered, 6 are puts, for a total amount of $241,558, and 4 are calls, for a total ...

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and ...

Zydus Lifesciences reacted sharply to the development in Tuesday's trade with the counter rising 5.23 percent to an intraday high of Rs 1,011.75 per share on the NSE.

Businesspeople, healthcare workers, a teacher and a former England football manager are among those from the Harrogate District to receive awards in The King’s New Year Honours List 2025.

The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock ...

CVS Health Corp. shares dipped below $50 on Thursday ... Separately, PBMs are being sued by the Federal Trade Commission. The industry is pushing back, saying the lawsuits are without merit ...

In September, the Federal Trade Commission sued the PBMs owned by CVS, UnitedHealth and Cigna, alleging they artificially raised prices on insulin drugs. CVS is a PBM through its CVS Caremark ...

In addition, the Federal Trade Commission released an interim report on July 9 that examined how six major pharmacy benefit managers, CVS Caremark, Optum Rx, Humana, MedImpact, Prime Therapeutics ...